Combination therapy using Cel-CSO/Taxol NPs for reversing drug resistance in breast cancer through inhibiting PI3K/AKT/NF-κB/HIF-1α pathway. - Zeng H; Zeng X; Wang C; Wang G; Tian Q; Zhao J; Zhao L; Li R; Luo Y; Peng H; Zhang Z; Li X; et al. (Drug delivery and translational research, 2025)